Indications and Outcome of Pelvic Exenteration for Locally Advanced Primary and Recurrent Rectal Cancer

医学 盆腔切除术 危险系数 结直肠癌 外科 切除缘 淋巴结 癌症 多元分析 切除术 置信区间 内科学
作者
Aneel Bhangu,Simak Ali,Gina Brown,R. John Nicholls,Paris Tekkis
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
卷期号:259 (2): 315-322 被引量:114
标识
DOI:10.1097/sla.0b013e31828a0d22
摘要

The outcome of pelvic exenteration was compared in patients with locally advanced primary (LAP) cancer and recurrent rectal cancer (RRC).There are few reports comparing the results of pelvic exenteration for primary advanced rectal cancer and RRC.Consecutive patients undergoing pelvic exenteration between 2006 and 2011 were identified from a prospectively maintained database. The main endpoints were 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS).Of 100 exenterative operations, 55 were for LAP cancer and 45 for RRC. Exenteration of 1 pelvic compartment was required in 30 cases, 2 compartments in 49 cases, and 3 of 4 compartments in 21 cases. R0, R1, and R2 resections were achieved in 78, 15, and 7 cases, respectively. R0 rates were significantly higher in LAP cancer than in RRC (91% vs 62%, P = 0.001). Three-year DFS for R0, R1, and R2 resections was 67%, 49%, and 0%, respectively (P < 0.001). For R0 resections only, DFS in LAP cancer was 76% and 57% in RRC (P = 0.212). On multivariate analysis, a positive resection margin (hazard ratio, 4.04; P < 0.001) and positive lymph node staging (hazard ratio, 2.43; P = 0.022) were significant predictors of reduced DFS. Three-year LRFS for R0 resection was 86% for LAP cancer and 84% for RRC (P = 0.817). On multivariate analysis, only a positive resection margin was a significant predictor of reduced LRFS (hazard ratio, 5.48; P = 0.002).Resection margin status is more important than primary or recurrent cancer in predicting long-term outcome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天完成签到 ,获得积分10
刚刚
ray发布了新的文献求助10
刚刚
Hello应助wang采纳,获得10
1秒前
qq完成签到 ,获得积分10
1秒前
Jasper应助zoloft采纳,获得10
1秒前
年华完成签到,获得积分10
1秒前
3秒前
充电宝应助伯赏诗霜采纳,获得50
5秒前
ubiqutin完成签到,获得积分10
6秒前
大模型应助Anquan采纳,获得30
6秒前
搜集达人应助饱满的紫伊采纳,获得30
7秒前
科研通AI5应助海鸥海鸥采纳,获得10
8秒前
ubiqutin发布了新的文献求助10
8秒前
9秒前
浮浮世世发布了新的文献求助50
9秒前
zoloft完成签到,获得积分10
11秒前
忆韵完成签到,获得积分10
11秒前
susu完成签到,获得积分20
13秒前
隐形曼青应助YYJ25采纳,获得10
14秒前
14秒前
zoloft发布了新的文献求助10
15秒前
yhc完成签到,获得积分10
15秒前
季生发布了新的文献求助60
16秒前
老孙完成签到,获得积分10
17秒前
18秒前
汤浩宏完成签到,获得积分10
21秒前
21秒前
yudandan@CJLU发布了新的文献求助10
23秒前
Zkxxxx完成签到,获得积分10
23秒前
123完成签到,获得积分10
24秒前
大王卡完成签到,获得积分20
25秒前
25秒前
机智的紫丝完成签到,获得积分10
25秒前
TT发布了新的文献求助10
26秒前
田様应助啥,这都是啥采纳,获得10
29秒前
辛勤的孤容完成签到,获得积分10
30秒前
30秒前
30秒前
petrichor应助优美的跳跳糖采纳,获得1020
30秒前
科研通AI2S应助fleee采纳,获得10
30秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527998
求助须知:如何正确求助?哪些是违规求助? 3108225
关于积分的说明 9288086
捐赠科研通 2805889
什么是DOI,文献DOI怎么找? 1540195
邀请新用户注册赠送积分活动 716950
科研通“疑难数据库(出版商)”最低求助积分说明 709849